Evaluation of cycloserine in the treatment of Alzheimer's disease
| Autor: | Benes C, Herting R, Schwartz P, Jhee Ss, Fakouhi Td, Sramek Jj, Cutler Nr, Swabb Ea, Hantsburger G |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Male
medicine.medical_specialty Drug Administration Schedule Central nervous system disease Placebos 03 medical and health sciences 0302 clinical medicine Degenerative disease Double-Blind Method Alzheimer Disease Internal medicine medicine Explicit memory Humans Memory disorder Psychiatry Antibiotics Antitubercular Aged Dose-Response Relationship Drug Cycloserine Cognitive disorder Middle Aged medicine.disease 030227 psychiatry Psychiatry and Mental health Female Neurology (clinical) Implicit memory Geriatrics and Gerontology Alzheimer's disease Psychology Cognition Disorders 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Journal of geriatric psychiatry and neurology. 8(4) |
| ISSN: | 0891-9887 |
| Popis: | This multicenter study evaluated the efficacy and safety of cycloserine and measured its effects on explicit and implicit memory tests in patients with Alzheimer's disease (AD). Four hundred ten patients with AD, aged 50 years or older, were enrolled in this parallel-group, double-blind, placebo-controlled, randomized trial of 5,15, or 50 mg cycloserine or placebo twice daily, and 403 entered the double-blind treatment phase. Two hundred sixty-five patients completed the entire 26-week treatment phase. There were no baseline differences among the four treatment groups. Cognitive Drug Research (CDR) efficacy assessments showed no differences between active treatments and placebo from baseline to study weeks 2, 6, 14, or 26. Patients receiving 15 mg of cycloserine improved significantly on one section of an implicit memory test. No differences among treatments were observed for any other assessment scales evaluated. The incidence and severity of adverse events were similar across treatment groups. Cycloserine was well tolerated but did not demonstrate consistent evidence of efficacy during the course of therapy. Higher doses may be necessary to achieve efficacy in the AD population and do not appear to be precluded by the adverse event profile seen in this study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|